Tenofovir resistance can lead to the option of switching to antiviral therapy with regimens such as entecavir or interferon. Tenofovir is currently the commonly used first-line drug for the treatment of hepatitis B virus infection, and the likelihood of resistance is extremely low. During antiviral treatment for hepatitis B, resistance to the antiviral may manifest itself in the form of increased levels of hepatitis B virus replication and liver function impairment. When tenofovir resistance occurs, it may be due to mutation of certain sites of the viral gene, and can be switched to entecavir antiviral therapy under the guidance of a doctor. If there is no contraindication to the use of interferon in the case of tenofovir resistance, interferon can also be used for antiviral treatment. However, the side effects of interferon are relatively greater, and changes in blood count and liver function need to be closely monitored. If tenofovir resistance is detected, it is recommended to consult a doctor promptly.